https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

Christoph D. Spinner
Conference Coverage

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference
News

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Putting test tubes into the holder
News

This Week in HIV Research: I Screen, You Screen, We All Screen for HPV-Related Cancers

May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.

Promo Image
News

This Week in HIV Research: Exorcizing Our PrEP Demons

Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.

Dual Maintenance Therapy With Dolutegravir + Rilpivirine Img
News Analysis

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

marijuana buds spilling out of a prescription bottle

Why HIV Care Providers Should Discuss Marijuana Use With Their Patients

What are the benefits and risks of marijuana use for people living with HIV? The answer is complicated, and explains why clinician-patient communication on the issue is increasingly important.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo)
News

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

Promo Image

This Week in HIV Research: Where Are the Cervical Cancer Screens?

Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.

Efavirenz Side Effects and Other Drug-Drug Interactions Are Common in Ugandan Cohort Img
Uganda

Efavirenz Side Effects and Other Drug-Drug Interactions Are Common in Ugandan Cohort

Drug-drug interactions and side effects, associated with currently-used first-line antiretroviral therapy, are under-reported and managed in Uganda.

China Approves Albuvirtide: A Once-Weekly Injectable Entry Inhibitor Img
China

China Approves Albuvirtide: A Once-Weekly Injectable Entry Inhibitor

On June 6, 2018, without news from the U.S. FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.